Download Medical Notes on Diabetes Costs and Affordability in the United States

Diabetes Costs and Affordability in the United States Medical Notes

About This Presentation

Description:This report titled, “Diabetes Costs and Affordability in the United States” by the IQVIA Institute provides a detailed analyses around diabetes drug pricing, including list price, net manufacturer price, and out-of-pocket costs for patients as a function of various insurance programs. The report also looks at prescription abandonment related to out-of-pocket costs, and how these costs can interrupt a patient’s ability to pay. The report examines the impact of insurance coverage and finds that commercially-insured patients have higher initial cost exposure than Medicare patients, but can use coupons to offset costs and a significant proportion are doing so, such that their final out-of-pocket costs are similar to that of Medicare patients. Finally, the report details current U.S. policies and other shifts in the diabetes landscape that will impact diabetes spending over the next few years

Tags:Diabetes Costs, Diabetes, United States, diabetes drug, pricing, healthcare, medical, insurance programs, prescription abandonment, Medicare patients

Published on: Jul 20, 2020 | Views : 1312 | Downloads : 0

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

Epigenetics

Marketing of Healthcare Services

Importance of food we eat and physical activity etc on our wellness

The Amazing Trends in Wellness Retail

PUBLIC HEALTH PROGRAMMES and PHARMACOVIGILANCE

Drug Development with Dutch Public Funding

The financialisation of Big Pharma

Global pharma and Indian pharmaceutical industry: Prospects for growth

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2019 - Booklet 1

Pharma 2020 Virtual R and D a paper on the future of the pharmaceutical industry

HEALTH A TO Z